EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 370 filers reported holding EXELIXIS INC in Q3 2020. The put-call ratio across all filers is 2.74 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $200,000 | -19.4% | 11,000 | 0.0% | 0.01% | -30.0% |
| Q1 2021 | $248,000 | +12.2% | 11,000 | 0.0% | 0.01% | 0.0% |
| Q4 2020 | $221,000 | -17.8% | 11,000 | 0.0% | 0.01% | -23.1% |
| Q3 2020 | $269,000 | +3.1% | 11,000 | 0.0% | 0.01% | -7.1% |
| Q2 2020 | $261,000 | +38.1% | 11,000 | 0.0% | 0.01% | +16.7% |
| Q1 2020 | $189,000 | -2.6% | 11,000 | 0.0% | 0.01% | +20.0% |
| Q4 2019 | $194,000 | -0.5% | 11,000 | 0.0% | 0.01% | -9.1% |
| Q3 2019 | $195,000 | -17.0% | 11,000 | 0.0% | 0.01% | -21.4% |
| Q2 2019 | $235,000 | -10.3% | 11,000 | 0.0% | 0.01% | -12.5% |
| Q1 2019 | $262,000 | +21.3% | 11,000 | 0.0% | 0.02% | 0.0% |
| Q4 2018 | $216,000 | +8.5% | 11,000 | -2.2% | 0.02% | +33.3% |
| Q3 2018 | $199,000 | -59.5% | 11,250 | -50.0% | 0.01% | -25.0% |
| Q2 2018 | $491,000 | +97.2% | 22,500 | +100.0% | 0.02% | -5.9% |
| Q1 2018 | $249,000 | -27.2% | 11,250 | 0.0% | 0.02% | -26.1% |
| Q4 2017 | $342,000 | – | 11,250 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |